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Background: BK virus infection has emerged as a major complication in kidney transplantation leading to a
significant reduction in graft survival. There are currently no proven strategies to prevent or treat BK virus infection.
Quinolone antibiotics, such as levofloxacin, have demonstrated activity against BK virus. We hypothesize that
administration of a quinolone antibiotic, when given early post-transplantation, will prevent the establishment of BK
viral replication in the urine and thus prevent systemic BK virus infection.
Methods/design: The aim of this pilot trial is to assess the efficacy, safety and feasibility of a 3-month course of
levofloxacin in the kidney transplant population. This is a multicenter, randomized, double-blind,
placebo-controlled trial with two parallel arms conducted in 11 Canadian kidney transplant centers. A total of 154
patients with end-stage renal disease undergoing kidney transplantation will be randomized to receive a 3-month
course of levofloxacin or placebo starting in the early post-transplant period. Levofloxacin will be administered at
500 mg po daily with dose adjustments based on kidney function. The primary outcome will be the time to
occurrence of BK viruria within the first year post-transplantation. Secondary outcomes include BK viremia, measures
of safety (adverse events, resistant infections,Clostridium difficile-associated diarrhea), measures of feasibility
(proportion of transplanted patients recruited into the trial), proportion of patients adherent to the protocol, patient
drop-out and loss to follow-up,and use of quinolone antibiotics outside of the trial protocol.
Discussion: Results from this pilot study will provide vital information to design and conduct a large, multicenter
trial to determine if quinolone therapy decreases clinically meaningful outcomes in kidney transplantation. If
levofloxacin significantly reduces BK viruria and urine viral loads in kidney transplantation, it will provide important
justification to progress to the larger trial. If the full trial shows that levofloxacin significantly reduces BK infection
and improves outcomes, its use in kidney transplantation will be strongly endorsed given the lack of proven
therapies for this condition.
Trial registration: This trial was funded by the Canadian Institutes of Health Research (grant number:222493) and is
registered at ClinicalTrials.gov (NCT01353339).
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Kidney transplantation is the treatment of choice for end-
stage renal disease as it prolongs survival [1], improves
quality of life [2] and is less costly when compared to
dialysis [3]. Acute rejection, once the major obstacle to
successful kidney transplantation, has now been reduced
to historically low levels (10% in 2005 [4]). This major ad-
vancement in care, however, has been replaced by a new
threat, BK virus infection. BK virus is a polyomavirus that
occurs worldwide with a prevalence of 60 to 80% in the
general population [5]. In kidney transplant recipients, im-
munosuppression leads to reactivation of the virus. BK
virus replication progresses through specific stages:
appearing first in the urine (BK viruria), then in the blood
(BK viremia) and finally in the kidney transplant as an in-
flammatory nephritis (BK virus nephropathy) [6]. BK virus
nephropathy generally has a poor prognosis with an
average transplant failure rate of 46% but reaching as high
as 100% in some series [7]. A recent series, however, has
shown a more favourable prognosis [8]. In a cohort of pa-
tients with definitive BK virus nephropathy, 92% had
complete viral clearance with no graft losses at a median
follow-up of 34 months [8].
Except for one study published in 1980 [9], there are no
randomized controlled trials (RCTs) evaluating strategies
to prevent or treat BK viruria, viremia or nephropathy.
Based on uncontrolled data, experts [6,10,11] and guide-
lines [5,7] have recommended that screening be adopted
to detect BK viruria or viremia followed by a reduction in
immunosuppression. Intuitively a good idea, this approach
is problematic since many patients do not actually clear
the virus with this strategy [12-14], immunosuppression
reduction can lead to acute and chronic rejection [12,15],
and, most importantly, long-term outcomes with this
screening strategy remain uncertain [16].
We propose to conduct a RCT to determine if we can
prevent BK virus infection from occurring rather than
trying to treat the virus once replication has been
established. Prophylactic strategies such as this are fami-
liar to kidney transplant patients and physicians as they
have become the standard of care for the prevention of
Cytomegalovirus (CMV) [17] and Pneumocystis infection
[18]. Quinolone antibiotics are safe, commonly used medi-
cations [19] that also have antiviral properties against BK
virus [20,21]. We hypothesize that the administration of a
quinolone, if given early post-transplantation, will prevent
BK viral replication in the urine and thus prevent systemic
BK virus infection. Preliminary data in kidney transplant
recipients have supported this preventive strategy.
Methods/design
This pilot study is a multicenter, double-blind, RCT
comparing a 3-month course of the quinolone antibiotic,
levofloxacin, to placebo in 154 kidney transplantrecipients. This study has been approved by the Ottawa
Hospital Research Ethics Board, Ottawa, ON, Canada
(protocol number: 2010292-01H).
Patient population
The following patients are eligible for this trial: 1) primary
or repeat kidney transplant recipients (deceased or living
donor); and 2) adults ≥18 years of age.
Exclusion criteria include: 1) patient unable to pro-
vide informed consent; 2) greater than 5 days post-
transplantation; 3) BK virus nephropathy with a previous
transplant; 4) history of allergic reaction to any quinolone
antibiotic; 5) history of quinolone-associated tendonitis or
tendon rupture; 6) corrected QT interval ≥450 ms; 7) ta-
king medication known to prolong the QT interval, such
as class IA antiarrhythmic drugs (for example quinidine,
procainamide, disopyramide), class III antiarrhythmic
drugs (for example amiodarone, sotalol), azole antifungals
(for example fluconazole) or macrolide antibiotics (for ex-
ample erythromycin); 8) pregnant or breastfeeding, since
the safety of levofloxacin in these settings is not esta-
blished; 9) require quinolone antibiotic for >14 days (for
example for UTI prophylaxis); 10) received a multiorgan
transplant (for example kidney-pancreas); 11) currently
enrolled in another interventional trial; 12) previously en-
rolled in this study; 13) history of rhabdomyolysis [22];
and 14) significant allergic reactions to ≥3classes of anti-
biotics, since these patients may have no other option
other than quinolones for treatment of common post-
transplant infection.
Trial intervention
The target dose of levofloxacin is 500 mg daily for 3
months. With normal kidney function, a single 500 mg
tablet of levofloxacin will produce a maximal urinary
drug concentration of 406 mg/l [23]. At a concentration
of 250 μg/ml, levofloxacin was shown to inhibit 3/8 BK
virus isolates [20]. At a concentration of 500 μg/ml,
levofloxacin was able to inhibit the remaining 5/8 iso-
lates [20]. Thus, we expect that the 500 mg tablet of
levofloxacin given daily will result in sufficient urinary
drug concentration to inhibit BK virus replication. Since
this is a proof of concept pilot trial there are no
published data to guide the duration of therapy. Given
that 80 to 85% of BK virus infections begin within the
first 3 months post-transplantation, a 3-month course of
levofloxacin should prevent the majority of infections
[24,25]. While 2 to 4 weeks of therapy might be the most
conservative approach with regards to safety, we believe
this would be insufficient to effectively prevent BK virus
infection. Similarly, a prolonged course of therapy (for
example 6 to 9 months) might prevent more BK virus
infections but would have the potential for more adverse
events, such as the emergence of resistant organisms.
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lance between efficacy and safety appropriate for a pilot
study.
Levofloxacin is administered orally once daily in the
morning. The 500 mg daily dose is given as two 250 mg
capsules to allow for dose reductions if required. At each
study visit, creatinine clearance is estimated using the
Cockcroft-Gault formula [26] and the dose of levoflo-
xacin is adjusted based on Canadian guidelines [27]. The
medication is started as soon as the patient is able to
take oral medications but must be started within 5 days
post-transplant [28] to ensure early viral replication is
prevented. The levofloxacin has been re-encapsulated so
that the placebo is identical in appearance to the study
medication.Other trial maneuvers
Outside of the primary trial intervention, the only major
interventions that are being controlled are CMV and
Pneumocystis jirovecii infection prophylaxis. All parti-
cipants are receiving prophylaxis against CMV and
Pneumocystis based on established guidelines [29,30].
Consistent with current clinical practice, patients with a
significant unexplained and sustained increase in serum
creatinine undergo transplant biopsy. A set protocol has
been developed outlining when study medication must be
stopped (for example significant Clostridiumdifficile-asso-
ciated diarrhea, rash, tendonitis). Co-interventions that
might influence BK infection, such as immunosuppressive
medication use, are being thoroughly documented but not
controlled. Although immunosuppressive strategies are
somewhat variable between centers, mandating a strict
immunosuppressive regimen would have limited site par-
ticipation and generalizability of study findings. More im-
portantly, all immunosuppressive medications have been
associated with BK virus infection and the net state of
immunosuppression appears more important than indi-
vidual agents [6,31].
As per our eligibility criteria, the routine use of
quinolones for bacterial prophylaxis (for example urinary
tract infection (UTI)) is not permitted. The investigators
have agreed to not use quinolones for empiric antibiotic
therapy. If a quinolone is absolutely necessary, then inves-
tigators have this option for the safety of the patient. We
expect this situation to be rare given the choices of anti-
biotics available (for example cephalosporins, amoxicillin/
clavulanic acid, nitrofurantoin). A set protocol has been
developed to guide the sites on non-study use of
quinolones. Once cultures are available, patients are
switched to a non-quinolone regimen. If the infection is
only quinolone-sensitive or the patient is intolerant/aller-
gic to other antibiotics, then quinolone use (beyond 24 to
48 hours) is allowed. During this time, study medication(placebo or levofloxacin) is withheld. All non-study use of
quinolones is being thoroughly documented.
Protecting against bias
Patients are randomized using a web-based system. A per-
muted blocked randomization method stratified by center
is used to allocate patients. An independent statistician
has generated the randomization scheme. The rando-
mization process consists of a computer-generated ran-
dom listing of the treatment allocations stratified by
center in variable permuted blocks of 2 and 4. Only the in-
dependent statistician and designated research pharmacist
at the coordinating center has knowledge of the rando-
mization codes to ensure concealed randomization of the
patients. After screening the patient for eligibility and
obtaining informed consent, the study coordinator ac-
cesses the trial website and provides the subject’s unique
identification,as well as a confirmation of consent and eli-
gibility. The website returns the next available rando-
mization number.
In order to minimize selection and ascertainment
biases, physicians, nurses, investigators and research staff
are blinded to the randomization schemes and treat-
ments administered. The study medication and placebo
are identical in appearance. The designated research
pharmacist at the coordinating center is expressly for-
bidden to discuss individual treatment allocation with
the study team or any patients. In addition, the staff at
the central laboratory performing the BK virus measure-
ments are not aware of the patient’s treatment allocation.
Given that this trial is blinded, contamination and co-
interventions should not become imbalanced between
the treatment arms. We are documenting the use of co-
interventions that may have some impact on BK virus,
such as immunosuppressive drug selection, dose and
levels [6], leflunomide [6,32], cidofovir [6,33], and intra-
venous immunoglobulin [6,34].
Participant follow-up
Patients are being followed for 1 year after the time of
randomization. Study visits take place every 4 weeks for
the first 24 weeks, then at 32, 40 and 52 weeks. A 1-year
follow-up should be sufficient since only 1.0 to 1.3% of
patients develop viremia and only 3% develop viruria
beyond 40 weeks post-transplantation [24,35].
Outcome measures
The primary outcome of the pilot study is the time to
occurrence of BK viruria within the first year post-
transplantation [36]. BK viruria is defined as ≥500 copies/
ml of BK virus DNA in the urine, which corresponds to
the lower limit of detection for our BK virus assay for
urine samples. BK virus infection is determined at each
study visit (baseline; every 4 weeks for the first 24 weeks;
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in urine samples. We have established methods to per-
form quantitative real-time PCR (qPCR) for the detection
of BK virus at our central laboratory at the University of
Alberta, Edmonton, AB, Canada. The assay we are using
has been in clinical use for the provincial kidney trans-
plant programs and has been used as a reference assay for
clinical trials, including one funded by the National
Institutes of Health (NIH), Bethesda, MD, USA. Detailed
performance characteristics of the assay have been
published [37].
Secondary safety outcomes include: 1) incidence and type
of all adverse events; 2) incidence of acute rejection; 3) inci-
dence of microbiologically confirmed C difficile-associated
diarrhea; 4) incidence of other infections (viral, bacterial,
fungal) based on established guidelines; 5) incidence of
quinolone resistance where a quinolone would have been a
therapeutic option (for example Escherichia coli UTI); 6) ef-
fect of levofloxacin on immunosuppressive drug doses and
blood levels [38-40]; and 7) transplant failure and mortality.
Secondary feasibility outcomes include: 1) number of
patients transplanted during the recruitment period who
are randomized into the trial; 2) proportion of random-
ized participants who are adherent to the protocol. Par-
ticipants who take at least 80% of study medication and
do not report any episodes of non-adherence will be
classified as adherent. Medication use will be measured
by pill count at each study visit. In addition, the partici-
pants will be questioned about any missed doses. Based
on data from the literature [41-44] and the fact that our
trial involves 3 months of therapy, we will judge this
outcome to be successful if >75% of participants are ad-
herent; 3) use of quinolones outside of the protocol; and
4)proportion of patient drop-out and loss to follow-up.
Secondary clinical outcomes include quantitative BK
viral load in urine and the time to occurrence of BK
viremia (defined as ≥25 copies/ml of BK virus DNA in
the plasma).
Sample size
Based on data from the literature, we estimate that 35%
of patients in the placebo group will develop BK viruria
by 1-year post-transplantation [24]. In order to detect an
absolute reduction in BK viruria of 20% (from 35 to
15%) with a two-sided alpha error of 0.05, a beta error of
0.2 and a 5% loss to follow-up rate, we would need 154
patients in total (77 per group). The minimal clinically
important difference of 20% was justified based on a sur-
vey of experts from the Canadian Renal Transplant
Study Group. The investigators wanted to see a substan-
tial effect on viruria in order to justify proceeding with a
larger trial examining the more clinically relevant end-
point of time to doubling serum creatinine, transplant
failure or death.Statistical analysis
Baseline characteristics of patients in the two treatment
arms will be assessed using frequency distributions and
univariate descriptive statistics, including measures of cen-
tral tendency and dispersion. Analyses will be performed
by intention-to-treat. Since this is a pilot study to assess
biologic efficacy, the intention-to-treat analysis will be
supplemented by a sensitivity analysis that excludes pa-
tients who did not complete the allocated treatment plan.
The primary analysis will use a nonparametric log-rank
test, stratified by center, to compare the time to occur-
rence of BK viruria between the control and levofloxacin
treatment groups. Kaplan-Meier survival curves will also
be plotted to visually assess differences in incidence over
time.
For secondary safety outcomes, the proportion of ad-
verse events occurring in each treatment arm will be
compared using an unadjusted chi-square test or Fisher’s
exact test if cell sizes are small. We will evaluate overall
adverse events as well as specific serious adverse events
(for example C difficile-associated diarrhea). For the
secondary feasibility outcome of recruitment, we will
calculate the proportion (and 95% confidence interval)
of all patients transplanted during the recruitment period
who are randomized into the trial. In addition, we will cal-
culate the proportion of patients that are eligible but con-
sent declined, eligible but not approached and not eligible.
These analyses will be performed at each site and for the
trial overall. For the secondary feasibility outcomes of
adherence, non-study quinolone use, drop-out and loss to
follow-up, the proportion of each outcome will be com-
pared between the arms with an unadjusted chi-square or
Fisher’s exact test. Since this is a pilot study, we have not
planned for any formal interim analyses.
Discussion
BK virus infection has emerged as a major complication
in kidney transplantation. There are no proven strategies
to prevent or treat BK virus infection. This trial will
assess the efficacy, safety and feasibility of a 3-month
course of levofloxacin to prevent BK virus infection fol-
lowing kidney transplantation. While there are concerns
about possible antimicrobial resistance and complica-
tions, such as C difficile-associated diarrhea, we are
closely monitoring safety and adverse events as part of
this trial. Results from this pilot study will provide vital
information to design and conduct a large, multicenter
trial to determine if levofloxacin therapy decreases major
clinical outcomes, such as biopsy-proven BK nephropa-
thy or graft loss in kidney transplantation. If levofloxacin
significantly reduces BK viruria and urine viral loads in
kidney transplantation, it will provide strong support of
biologic effect and justification to progress to the larger
trial. If the full trial shows that levofloxacin significantly
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this preventive therapy will be a major innovation in the
management of kidney transplant recipients, especially
given the lack of proven therapies for this condition.
Trial status
The first participant was randomized in December 2011
and recruitment is ongoing as of 28 May 2013.
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